Parkinson Disease

56 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Brain Diseases, Nervous System Diseases, Neurodegenerative Diseases

Treatments and conditions

Parkinson Disease
Treatment and conditionWhere it standsTrials
1 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
120 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
60 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Aav-gad for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-1005 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Activa PC+S Neurostimulator for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS (aDBS) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS delivered through AlphaDBS IPG System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
adaptive deep brain stimulation + conventional deep brain stimulation for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
aDBS-Extended (Medtronic Percept™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ambroxol for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
apomorphine infusion for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
autologous dopaminergic cell implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous midbrain dopamine neurons for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 225 mg for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CVN424 150 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
CVN424 75 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Diet + Exercise + Meditation for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DSP-1083 implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Focused Transcranial Ultrasound for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High-Intensity Aerobic Exercise (AE) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ketamine for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lixisenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3884961 + Sirolimus + Methylprednisolone for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Modified deep cervical Lymphatic-Venous Anastomosis for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 high dose (15 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 low dose (1 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 1 (3 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 2 (7 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prasinezumab for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Psilocybin for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin + PIMAVANSERIN for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tavapadon for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
The LFP Beta aDBS System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.